Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsOVID +1.07%34 PS Ratio is 188.00 as of Aug. 15, 2026, which is 138% above its 10-year median of 79.05. GuruFocus rates OVID with a GF Score™ of 34/100 and a GF Value™ of $0.99 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 931 Biotechnology companies, Ovid Therapeutics ranks worse than 72.18% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ovid Therapeutics's share price is $2.82.
Ovid Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.02. Hence, Ovid Therapeutics's PS Ratio for today is 188.00.
Warning Sign:
Ovid Therapeutics Inc stock PS Ratio (=188) is close to 2-year high of 188.
The historical rank and industry rank for Ovid Therapeutics's PS Ratio or its related term are showing as below:
OVID'
s PS Ratio Range Over the Past 10 Years
Min: 0.86 Med: 79.05 Max: 1865
Current: 188
During the past 11 years, Ovid Therapeutics's highest PS Ratio was 1865.00. The lowest was 0.86. And the median was 79.05.
OVID's PS Ratio is ranked worse than 72.18% of 931
companies
in the Biotechnology industry
Industry Median: 9.55
vs OVID: 188.00
Ovid Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Ovid Therapeutics was -83.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 67.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -48.20% per year.
During the past 11 years, Ovid Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 67.10% per year. The lowest was -86.20% per year. And the median was -69.70% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ovid Therapeutics PS Ratio Related Terms
Ovid Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ovid Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ovid Therapeutics's Share Price of today is $2.82. Ovid Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ovid Therapeutics (OVID) has a PS Ratio of 188.00 as of Aug. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ovid Therapeutics and its competitors. This is 138% above median its historical median of 79.05. Over the past decade, Ovid Therapeutics' PS Ratio has ranged from 0.86 to 1,865.00. According to the industry distribution chart, Ovid Therapeutics ranks #672 out of 931 companies in the Biotechnology industry, placing it in the top 72.2%.
Is Ovid Therapeutics' PS Ratio too high?
Ovid Therapeutics' current PS Ratio of 188.00 is 138% above median its 10-year median of 79.05. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 1,865.00. The Biotechnology industry median PS Ratio is 9.55. Ovid Therapeutics' value of 188.00 is 1868.6% above this industry median. Based on the distribution chart, Ovid Therapeutics ranks #672 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' PS Ratio compare to SGMT and CABA?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #672 out of 931 companies for PS Ratio. This places Ovid Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.55. Ovid Therapeutics' value of 188.00 is 1868.6% above this benchmark. Historically, Ovid Therapeutics' own PS Ratio has ranged from 0.86 to 1,865.00 over the past decade. While the company's 10-year median is 79.05 vs. the industry median of 9.55, Ovid Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.55, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovid Therapeutics's current PS Ratio of 188.00 is 1868.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ovid Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current PS Ratio is 188.00, which is 138% above median its own 10-year median of 79.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.99, compared to a current price of $2.82 — trading 184.8% above its estimated fair value. The current PS Ratio is 188.00, which is 138% above median its 10-year median of 79.05 and 1868.6% above the Biotechnology industry median of 9.55. Ovid Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current PS Ratio is 188.00 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued.
The current stock price of $2.82 is trading 184.8% above its estimated GF Value™ of $0.99.
GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.
Key valuation signals for OVID:
PS Ratio: 188.00 (138% above median its 10-year median of 79.05)
GF Value™: $0.99 vs. price of $2.82 (184.8% above fair value)
Industry Position: 1868.6% above the Biotechnology median (#672 of 931)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score
Get the complete analysis for OVID
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
